Blüml Stephan
Klinik für Innere Medizin III/Abteilung für Rheumatologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
Z Rheumatol. 2020 Apr;79(3):223-231. doi: 10.1007/s00393-020-00766-7.
In recent years tremendous progress has been made in the therapeutic management of rheumatoid arthritis. Rheumatologists now have a large armamentarium of highly efficient drugs with different mechanisms of action at their disposal. These new drugs consist of biologicals (biological disease-modifying antirheumatic drugs, bDMARDs) as well as targeted synthetic DMARDs (tsDMARD). A common feature of these new drugs for treatment of rheumatoid arthritis is that the molecular target of the drug is known, which is not the case for conventional DMARDs. With the help of the new drugs, the therapeutic goal of inducing remission in patients with rheumatoid arthritis has become reality for many patients. Nevertheless, there is still a significant proportion of patients who do not adequately respond to all available drugs, leaving room for still further improvement. This review gives a short overview on the currently available and effective substances for the treatment of rheumatoid arthritis.
近年来，类风湿关节炎的治疗管理取得了巨大进展。风湿病学家现在有大量具有不同作用机制的高效药物可供使用。这些新药包括生物制剂（生物改善病情抗风湿药，bDMARDs）以及靶向合成抗风湿药（tsDMARD）。这些用于治疗类风湿关节炎的新药的一个共同特点是药物的分子靶点是已知的，而传统抗风湿药并非如此。借助这些新药，诱导类风湿关节炎患者缓解的治疗目标已成为许多患者的现实。然而，仍有相当一部分患者对所有可用药物反应不佳，仍有进一步改进的空间。本综述简要概述了目前可用于治疗类风湿关节炎的有效药物。
